Voronoi Inc
310210
Company Profile
Business description
Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders. It is principally focused on developing targeted therapies for anticancer drugs such as lung and breast cancer. Its pipeline products are: VRN11, VRN16, VRN10, VRN19, VRN07, VRN04, VRN06, and others.
Contact
32 Songdo Science-ro
18th floor, S Building
Songdo-dong, Songdo Techno Park IT Center
Yeonsu-gu
Incheon
KORT: +82 328304855
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
146
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.30 | 44.90 | 0.50% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,747.34 | 56.81 | 0.22% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,480.76 | 973.55 | 1.97% |
| NZX 50 Index | 13,468.62 | 135.22 | 1.01% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,704.00 | 43.80 | 0.51% |
| SSE Composite Index | 3,915.18 | 24.74 | 0.64% |